Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (6951)	8/21/2002 8:30:36 PM
From: Doc Bones	Read Replies (1) \| Respond to of 52153

Adam Feuerstein, unlike most writers, does answer his e-mail in my experience. In an earlier exchange I failed to change his mind on the value of VPHM's cash. The market has backed him on that [so far ;-) ], and has backed him all too spectacularly on his negative attitude toward biotech stocks in general, which I've criticized in the past. Here is our second correspondence: Adam, Congrats on being right very early on Iressa. Editing slips: "If you're keeping score at home, not a single drug in the EGF-inhibitor class has yet to post positive results in a controlled, phase III clinical trial" "has yet posted" not "has yet to post" (or "...drugs in the EGF-inhibitor class have yet to post a single positive result...."?) ----- "Bank of America" not "Banc of America" Regards, [Doc Bones] ************************** thanks [doc]. as for the grammar questions, i'll spot you "has yet posted" but banc of america is correct... the "c" in "banc" is a legal requirement to differentiate the investment bank from the retail bank... adam ---------------------------------------------------------- Adam Feuerstein Senior Writer TheStreet.com 415 733-8324